Use of Sitagliptin with Closed-Loop Technology to Decrease Postprandial Blood Glucose in Type 1 Diabetes

Journal of Diabetes Science and Technology

Volumn 11, Issue 3, 2017, Pages 602-610

  Underland, Lisa J ^a   Ilkowitz, Jeniece Trast ^a,b   Katikaneni, Ranjitha ^a   Dowd, Amy ^a   Heptulla, Rubina A ^a  

^a CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

artificial pancreas; closed loop; sitagliptin; type 1 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; INSULIN; PLACEBO; SITAGLIPTIN; ANTIDIABETIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL PANCREAS; BIOAVAILABILITY; BLOOD GLUCOSE MONITORING; BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN SENSITIVITY; MALE; MIXED MEAL TOLERANCE TEST; MONOTHERAPY; PHYSICAL EXAMINATION; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SCREENING; SINGLE DRUG DOSE; YOUNG ADULT; ADOLESCENT; BLOOD; COMBINATION DRUG THERAPY; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; PROCEDURES;

ADOLESCENT; ADULT; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; POSTPRANDIAL PERIOD; SITAGLIPTIN PHOSPHATE; YOUNG ADULT;

EID: 85018995962     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296817699847     Document Type: Article

References (25)

1. Raman VS, Heptulla RA., New potential adjuncts to treatment of children with type 1 diabetes mellitus. Pediatr Res. 2009; 65: 370-374.
2. Heptulla RA, Allen HF, Gross TM, Reiter EO., Continuous glucose monitoring in children with type 1 diabetes: before and after insulin pump therapy. Pediatr Diabetes. 2004; 5: 10-15.
3. Manuel-y-Keenoy B, Vertommen J, Abrams P, et al. Postprandial glucose monitoring in type 1 diabetes mellitus: use of a continuous subcutaneous monitoring device. Diabetes Metab Res Rev. 2004; 20 (suppl 2): S24-S31.
4. Ansarullah Lu Y, Holstein M, DeRuyter B, Rabinovitch A, Guo Z., Stimulating beta-cell regeneration by combining a GPR119 agonist with a DPP-IV inhibitor. PLOS ONE. 2013; 8: e53345.
5. Ballav C, Gough SC., Safety and efficacy of sitagliptin-metformin in fixed combination for the treatment of type 2 diabetes mellitus. Clin Med Insights Endocrinol Diabetes. 2013; 6: 25-37.
6. Jeha GS, Heptulla RA., Newer therapeutic options for children with diabetes mellitus: theoretical and practical considerations. Pediatr Diabetes. 2006; 7: 122-138.
7. Ahren B., Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes. World J Diabetes. 2014; 5: 40-51.
8. Nadkarni P, Chepurny OG, Holz GG., Regulation of glucose homeostasis by GLP-1. Prog Mol Biol Transl Sci. 2014; 121: 23-65.
9. Asai S, Ohta A, Kato H, et al. Effect of sitagliptin on glycemic control and beta cell function in Japanese patients given basal-supported oral therapy for type 2 diabetes. Endocr J. 2014; 61: 1213-1220.
10. Ando K, Nishimura R, Seo C, Tsujino D, Sakamoto M, Utsunomiya K., Comparing postprandial efficacy in type 2 diabetic patients receiving mitiglinide and sitagliptin by using continuous glucose monitoring: a pilot study. Expert Opin Pharmacother. 2014; 15: 2479-2485.
11. Capuano A, Sportiello L, Maiorino MI, Rossi F, Giugliano D, Esposito K., Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy-focus on alogliptin. Drug Des Devel Ther. 2013; 7: 989-1001.
12. Alba M, Ahren B, Inzucchi SE, et al. Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function. Diabetes Obes Metab. 2013; 15: 1101-1110.
13. Murai K, Katsuno T, Miyagawa J, et al. Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data. Drugs R D. 2014; 14: 301-308.
14. Farngren J, Persson M, Schweizer A, Foley JE, Ahren B., Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes. J Clin Endocrinol Metab. 2012; 97: 3799-3806.
15. Brunton S., GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? Int J Clin Pract. 2014; 68: 557-567.
16. Boland CL, Degeeter M, Nuzum DS, Tzefos M., Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors. Ann Pharmacother. 2013; 47: 490-505.
17. Zisser H, Renard E, Kovatchev B, et al. Multicenter closed-loop insulin delivery study points to challenges for keeping blood glucose in a safe range by a control algorithm in adults and adolescents with type 1 diabetes from various sites. Diabetes Technol Ther. 2014; 16: 613-622.
18. Dhalla S, Zumbo BD, Poole G., A review of the psychometric properties of the CRAFFT instrument: 1999-2010. Curr Drug Abuse Rev. 2011; 4: 57-64.
19. Dallal EG,. Randomization.com. 3, 2017. http://www.randomization.com.
20. Loh SH., Diluted glucose oxidase reagents adapted for use with Analox GM 7 Analyser for measuring plasma glucose. Ann Clin Biochem. 1989; 26 (pt 5): 453-454.
21. Crandall JP, Oram V, Trandafirescu G, et al. Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A Biol Sci Med Sci. 2012; 67: 1307-1312.
22. Ellis SL, Moser EG, Snell-Bergeon JK, Rodionova AS, Hazenfield RM, Garg SK., Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med. 2011; 28: 1176-1181.
23. Garg SK, Moser EG, Bode BW, et al. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocr Pract. 2013; 19: 19-28.
24. Kim SS, Kim IJ, Lee KJ, et al. Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: a multicenter, randomized, double-blind study. J Diabetes. 2016; 27: 1753-0407.
25. Chen XW, He ZX, Zhou ZW, et al. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015; 42: 999-1024.